Zurück

Wählen Sie Ihre Region

Corporate

Europa:

Flagge Albanien Albanien Flagge Bosnien-Herzegowina Bosnien-Herzegowina Flagge Bulgarien Bulgarien Flagge Kroatien Kroatien Flagge Zypern Zypern Flagge Montenegro Montenegro Flagge Tschechien Tschechien Flagge Dänemark Dänemark Flagge Estland Estland Flagge Spanien Spanien Flagge Kosovo Kosovo Flagge Litauen Litauen Flagge Lettland Lettland Flagge Luxemburg Luxemburg Flagge Mazedonien Mazedonien Flagge Deutschland Deutschland Flagge Polen Polen Flagge Portugal Portugal Flagge Rumänien Rumänien Flagge Serbien Serbien Flagge Slowakei Slowakei Flagge Slowenien Slowenien Flagge Schweiz Schweiz Flagge Schweden Schweden Flagge Türkei Türkei Flagge Ungarn Ungarn Flagge Großbritannien Großbritannien Flagge Italien Italien

Asien:

Flagge UAE UAE Flagge Hong Kong Hong Kong Flagge Kuwait Kuwait Flagge Libanon Libanon

Afrika:

Flagge Südafrika Südafrika

Vereinbaren Sie ein Beratungsgespräch über Stammzellen

Mehr erfahren

Kontaktieren Sie uns noch heute!

Möchten Sie mehr über unsere Dienstleistungen erfahren? Füllen Sie das untenstehende Formular aus, und wir werden uns so schnell wie möglich mit Ihnen in Verbindung setzen, um Ihnen alle notwendigen Informationen zu geben und Ihre Fragen zu beantworten.

    Wir möchten Sie darauf hinweisen, dass die im Formular angegebenen personenbezogenen Daten von FamiCord Suisse mit Sitz in der Schweiz (BusinessPark Zug Sumpfstrasse 26, 6302 Zug) zur telefonischen Kontaktaufnahme im Zusammenhang mit der Erteilung von Serviceinformationen verarbeitet werden.

    Obraz

    Unsere
    Transplantationen

    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:

    Obraz
    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:
    Nr. Quelle Quellentyp Diagnose Medizinbereich Anwendungsjahr Therapie Land Alter des Empfängers
    301 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Belgium 48
    302 Apheresis Allogeneic Essential Thrombocythemia Hematology 2026 Standard Therapy USA 59
    303 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Ukraine 58
    304 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
    305 Apheresis Allogeneic B-ALL B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Netherlands 71
    306 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 59
    307 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 67
    308 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
    309 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 37
    310 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 66
    311 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 48
    312 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 15
    313 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2026 Standard Therapy USA 45
    314 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 61
    315 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 43
    316 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 64
    317 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 29
    318 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 69
    319 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 61
    320 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
    321 Apheresis Allogeneic Orofacial Myofunctional Disorders (OMDS); Primary Myelofibrosis (PMF) to secondary Acute Myeloid Leukemia (AML) Hematology 2026 Standard Therapy Germany 36
    322 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 66
    323 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 66
    324 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
    325 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 51
    326 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 25
    327 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 35
    328 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Finland 40
    329 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 49
    330 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
    331 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 67
    332 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 50
    333 Apheresis Allogeneic T Lymphblastic Leukemia/Lymphoma Hematology 2026 Standard Therapy Canada 43
    334 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy France 74
    335 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 67
    336 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 59
    337 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 44
    338 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy Poland 56
    339 Apheresis Autologous Anaplastic T Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Portugal 23
    340 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
    341 Apheresis Allogeneic T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 55
    342 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    343 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
    344 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 56
    345 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
    346 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 60
    347 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 75
    348 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 58
    349 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 74
    350 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
    351 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 70
    352 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 25
    353 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Sweden 65
    354 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 72
    355 Apheresis Allogeneic Lymphoma Burkitt Histiocytic Sarcoma Hematology 2026 Standard Therapy Greece 12
    356 Apheresis Allogeneic Acute Myelogenous Leukaemia Hematology 2026 Standard Therapy France 69
    357 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 69
    358 Apheresis Allogeneic Acute Myeloid Leukemia FLT3-ITD positive Hematology 2026 Standard Therapy Romania 11
    359 Apheresis Allogeneic Myelofibrosis (MF) Hematology 2026 Standard Therapy Lithuania 67
    360 Apheresis Allogeneic X-ALD (E 71.3) Hematology 2026 Standard Therapy Czechia 5
    361 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
    362 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 36
    363 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 56
    364 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
    365 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 39
    366 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 24
    367 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 62
    368 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
    369 Apheresis Allogeneic Other Malignancy Hematology 2026 Standard Therapy USA 71
    370 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 62
    371 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
    372 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 70
    373 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 26
    374 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 40
    375 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 68
    376 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
    377 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms Hematology 2026 Standard Therapy Spain 65
    378 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 63
    379 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 58
    380 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 44
    381 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 61
    382 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 54
    383 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Poland 11
    384 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 64
    385 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 64
    386 Apheresis autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 32
    387 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
    388 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 54
    389 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
    390 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 72
    391 Apheresis autologous Peripheral T-cell Lymphoma Hematology 2026 Standard Therapy Germany 56
    392 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    393 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    394 Apheresis autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 47
    395 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    396 Apheresis allogeneic Vexas-Syndrome with UBA1-Mutation Hematology 2026 Standard Therapy Germany 67
    397 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 27
    398 Apheresis allogeneic Primary Myelofibrosis PMF Hematology 2026 Standard Therapy Poland 57
    399 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 48
    400 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 67